New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - clonazepam 1 mg/ml - injection with diluent - 1 mg - active: clonazepam 1 mg/ml excipient: benzyl alcohol ethanol glacial acetic acid propylene glycol water for injection - most clinical forms of epilepsy in infants and children, in particular typical and atypical absences (lennox-gastaut syndrome), nodding spasms, primary or secondary generalised tonic-clonic seizures. in adults, rivotril may be used in all varieties of generalised epilepsy (including absence, myoclonic, akinetic, tonic and tonic-clonic seizures), and in partial (focal) epilepsy (including psychomotor seizures).

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - vinorelbine tartrate 13.85mg equivalent to to 10 mg vinorelbine - concentrate for injection - 10 mg/ml - active: vinorelbine tartrate 13.85mg equivalent to to 10 mg vinorelbine excipient: nitrogen water for injection - dbl™ vinorelbine injection concentrate is indicated as a single agent or in combination for 1. the treatment of non small cell lung cancer (nsclc), and 2. the second line treatment of advanced breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium nitroprusside, quantity: 50 mg - injection, solution - excipient ingredients: water for injections - dbl? sodium nitroprusside injection is indicated for:,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate.,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium nitroprusside, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - sodium nitroprusside baxter concentrated injection is indicated for:,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate.,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: water for injections - ephedrine hydrochloride injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - clonazepam, quantity: 1 mg - diluent, not applicable - excipient ingredients: water for injections - injection: intravenous use, for status epilepticus.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - octocog alfa, quantity: 2000 iu - injection, diluent for - excipient ingredients: water for injections - kogenate fs is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). it may also be used in patients with factor viii inhibitors (neutralising antibodies) who continue to respond to infused factor viii. kogenate fs does not contain von willebrand factor and hence is not indicated in von willebrands disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - octocog alfa, quantity: 3000 iu - injection, diluent for - excipient ingredients: water for injections - kogenate fs is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). it may also be used in patients with factor viii inhibitors (neutralising antibodies) who continue to respond to infused factor viii. kogenate fs does not contain von willebrand factor and hence is not indicated in von willebrands disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: sorbitol; sodium hydroxide; water for injections; lactic acid; dilute hydrochloric acid - irinotecan injection is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan injection is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - emicizumab, quantity: 60 mg - injection, solution - excipient ingredients: poloxamer; arginine; aspartic acid; water for injections; histidine - hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in adult and paediatric patients with haemophilia a (congenital factor viii deficiency) with or without factor viii inhibitors.